The withdrawal of the thyromimetic eprotirome

References

• Ladenson PW, Kristensen JD, Ridgway EC et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med. 362(10), 906–916 (2010).
   Google Scholar
• Sjouke B, Langslet G, Ceska R et al.. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled Phase 3 study. Lancet Diabetes Endocrinol.2(6), 455–463 (2014).
   Google Scholar
• Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128(19), 2113–2120 (2013).
   Google Scholar
• Pramfalk C, Pedrelli M, Parini P. Role of thyroid receptor beta in lipid metabolism. Biochim. Biophys. Acta 1812(8), 929–937 (2011).
   Google Scholar
• Bleicher L, Aparicio R, Nunes FM et al. Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. BMC Struct. Biol. 8, 8 (2008).
   Google Scholar
• Flamant F, Gauthier K. Thyroid hormone receptors: the challenge of elucidating isotype-specific functions and cell-specific response. Biochim. Biophys. Acta 1830(7), 3900–3907 (2013).
   Google Scholar
• Tancevski I, Eller P, Patsch JR, Ritsch A. The resurgence of thyromimetics as lipid-modifying agents. Curr. Opin. Investig. Drugs 10(9), 912–918 (2009).
   Google Scholar
• Shoemaker TJ, Kono T, Mariash CN, Evans-Molina C. Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs? Endocr. Pract. 18(6), 954–964 (2012).
   Google Scholar
• Wojcicka A, Bassett JH, Williams GR. Mechanisms of action of thyroid hormones in the skeleton. Biochim. Biophys. Acta 1830(7), 3979–3986 (2013).
   Google Scholar
• Grover GJ, Egan DM, Sleph PG et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-L-thyronine. Endocrinology 145(4), 1656–1661 (2004).
   Google Scholar
• Lin JZ, Martagon AJ, Hsueh WA et al. Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 153(12), 6136–6144 (2012).
   Google Scholar
• Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20(2), 522–528 (2000).
   Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 Phase II trials. J. Am. Coll. Cardiol. 63(13), 1278–1288 (2014).
   Google Scholar
• Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am. J. Cardiovasc. Drugs 13(4), 285–296 (2013).
   Google Scholar
• Bell DA, Hooper AJ, Watts GF, Burnett JR. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc. Health Risk Manag. 8, 651–659 (2012).
   Google Scholar
• Yadav R, France M, Younis N et al. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety. Expert Opin. Pharmacother. 13(9), 1345–1362 (2012).
   Google Scholar
• Sniderman AD, De Graaf J, Couture P, Williams K, Kiss RS, Watts GF. Regulation of plasma LDL: the apoB paradigm. Clin. Sci. (Lond.) 118(5), 333–339 (2010).
   Google Scholar
• Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 62(4), 479–491 (2013).
   Google Scholar
• Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol. 368(1–2), 17–29 (2013).
   Google Scholar
• Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acidactivated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid. Res. 49(2), 171–185 (2010).
   Google Scholar